Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial

Simple item page
dc.catalogadorjlo
dc.contributor.authorBueno Ramírez, Susan
dc.contributor.authorAbarca Villaseca, Katia
dc.contributor.authorGonzález Adonis, Pablo Andrés
dc.contributor.authorGálvez Arriagada, Nicolás Marcelo Salvador
dc.contributor.authorSoto Ramírez, Jorge Andrés
dc.contributor.authorDuarte Peñaloza, Luisa Fernanda
dc.contributor.authorSchultz Lombardic, Bárbara M.
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorGonzález Carreño, Liliana Andrea
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorRíos Raggio, Mariana
dc.contributor.authorMelo González, Felipe
dc.contributor.authorRivera Pérez, Daniela
dc.contributor.authorIturriaga, Carolina
dc.contributor.authorUrzúa Acevedo, Marcela del Pilar
dc.contributor.authorDomínguez De Landa, María Angélica
dc.contributor.authorAndrade Parra, Catalina Andrea
dc.contributor.authorBerríos Rojas, Roslye
dc.contributor.authorCanedo Marroquín, Giselda
dc.contributor.authorCovián, Camila
dc.date.accessioned2024-01-29T17:48:31Z
dc.date.available2024-01-29T17:48:31Z
dc.date.issued2021
dc.description.abstractThe ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.
dc.fuente.origenORCID-ene24
dc.identifier.doi10.1101/2021.03.31.21254494
dc.identifier.issn1058-4838
dc.identifier.urihttps://doi.org/10.1101/2021.03.31.21254494
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/81033
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan Marcela; 0000-0002-7551-8088; 113541
dc.information.autorucEscuela de Medicina; Abarca Villaseca, Katia; 0000-0003-0404-3887; 70281
dc.information.autorucEscuela de Psicología; González Adonis, Pablo Andrés; 0000-0001-7523-5363; 133334
dc.information.autorucFacultad de Ciencias Biológicas; Gálvez Arriagada, Nicolás Marcelo Salvador; 0000-0003-2046-7882; 215440
dc.information.autorucFacultad de Ciencias Biológicas; Soto Ramírez Jorge Andrés; 0000-0003-0335-9759; 237269
dc.information.autorucFacultad de Ciencias Biológicas; Duarte Peñaloza Luisa Fernanda; 0000-0003-1828-1800; 1031205
dc.information.autorucFacultad de Ciencias Biológicas; Schültz Lombardic, Bárbara Melinka; 0000-0002-6201-6978; 186964
dc.information.autorucFacultad de Ciencias Biológicas; Pacheco Ruidíaz, Gaspar Andrés; 0000-0001-5748-5027; 1047198
dc.information.autorucFacultad de Ciencias Biológicas; González Carreño, Liliana Andrea; S/I; 250114
dc.information.autorucFacultad de Ciencias Biológicas; Vázquez Hernández, Yaneisi; S/I; 1025308
dc.information.autorucFacultad de Ciencias Biológicas; Ríos Raggio, Mariana; S/I; 50388
dc.information.autorucFacultad de Ciencias Biológicas; Melo González Felipe Andrés; 0000-0002-3711-2407; 149763
dc.information.autorucFacultad de Ciencias Biológicas; Rivera Pérez, Daniela Belén; 0000-0002-3317-5080; 1175592
dc.information.autorucEscuela de Medicina; Iturriaga Ortiz, Carolina Alejandra; S/I; 1058623
dc.information.autorucActividades Universitarias-Dri; Urzúa Acevedo Marcela Del Pilar; 0000-0002-2371-620X; 4145
dc.information.autorucEscuela de Medicina; Domínguez De Landa María Angélica; 0000-0001-7477-7574; 131798
dc.information.autorucFacultad de Ciencias Biológicas; Andrade Parra, Catalina Andrea; 0000-0003-2623-1387; 234276
dc.information.autorucFacultad de Ciencias Biológicas; Canedo Marroquín Gisela Eliana; 0000-0001-8629-5847; 171972
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final32
dc.pagina.inicio1
dc.revistaClinical Infectious Diseases
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleInterim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
dc.typepreprint
sipa.codpersvinculados113541
sipa.codpersvinculados70281
sipa.codpersvinculados133334
sipa.codpersvinculados215440
sipa.codpersvinculados237269
sipa.codpersvinculados1031205
sipa.codpersvinculados186964
sipa.codpersvinculados1047198
sipa.codpersvinculados250114
sipa.codpersvinculados1025308
sipa.codpersvinculados50388
sipa.codpersvinculados149763
sipa.codpersvinculados1175592
sipa.codpersvinculados1058623
sipa.codpersvinculados4145
sipa.codpersvinculados131798
sipa.codpersvinculados234276
sipa.codpersvinculados171972
sipa.trazabilidadORCID;2024-01-15
Files
Collections
Artículos de revistas